Risk of seizures in transcranial magnetic stimulation: a clinical review to inform consent process focused on bupropion

被引:37
作者
Dobek, Christine E. [1 ]
Blumberger, Daniel M. [2 ]
Downar, Jonathan [3 ]
Daskalakis, Zafiris J. [2 ]
Vila-Rodriguez, Fidel [1 ]
机构
[1] Univ British Columbia, Fac Med, Noninvas Neurostimulat Therapies NINET Lab, Dept Psychiat, Vancouver, BC V6T 2A1, Canada
[2] Univ Toronto, Dept Psychiat, Ctr Addict & Mental Hlth, Toronto, ON, Canada
[3] Univ Toronto, Dept Psychiat, Univ Hlth Network, Toronto, ON, Canada
关键词
repetitive transcranial magnetic stimulation; seizures; bupropion; consent process; interaction; MAJOR DEPRESSIVE DISORDER; ADOLESCENT PATIENT; SUSTAINED-RELEASE; BRAIN-STIMULATION; CANADIAN NETWORK; SAFETY; GUIDELINES; MANAGEMENT; INDUCTION; RTMS;
D O I
10.2147/NDT.S91126
中图分类号
R74 [神经病学与精神病学];
学科分类号
100204 [神经病学];
摘要
Objective: When considering repetitive transcranial magnetic stimulation (rTMS) for major depressive disorder, clinicians often face a lack of detailed information on potential interactions between rTMS and pharmacotherapy. This is particularly relevant to patients receiving bupropion, a commonly prescribed antidepressant with lower risk of sexual side effects or weight increase, which has been associated with increased risk of seizure in particular populations. Our aim was to systematically review the information on seizures occurred with rTMS to identify the potential risk factors with attention to concurrent medications, particularly bupropion. Data sources: We conducted a systematic review through the databases PubMed, PsycINFO, and EMBASE between 1980 and June 2015. Additional articles were found using reference lists of relevant articles. Reporting of data follows Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Study selection: Two reviewers independently screened articles reporting the occurrence of seizures during rTMS. Articles reporting seizures in epilepsy during rTMS were excluded. Aytotal of 25 rTMS-induced seizures were included in the final review. Data extraction: Data were systematically extracted, and the authors of the applicable studies were contacted when appropriate to provide more detail about the seizure incidents. Results: Twenty-five seizures were identified. Potential risk factors emerged such as sleep deprivation, polypharmacy, and neurological insult. High-frequency-rTMS was involved in a percentage of the seizures. None of these seizures reported had patients taking bupropion in the literature review. One rTMS-induced seizure was reported from the Food and Drug Administration in a sleep-deprived patient who was concurrently taking bupropion, sertraline, and amphetamine. Conclusion: During the consent process, potential risk factors for an rTMS-induced seizure should be carefully screened for and discussed. Data do not support considering concurrent bupropion treatment as contraindication to undergo rTMS.
引用
收藏
页码:2975 / 2987
页数:13
相关论文
共 61 条
[1]
Seizure incidence in psychopharmacological clinical trials: An analysis of food and drug administration (FDA) summary basis of approval reports [J].
Alper, Kenneth ;
Schwartz, Kelly A. ;
Kolts, Russell L. ;
Khan, Arif .
BIOLOGICAL PSYCHIATRY, 2007, 62 (04) :345-354
[2]
[Anonymous], PSYCHIAT TIMES
[3]
[Anonymous], TRICYCLIC ANTIDEPRES
[4]
[Anonymous], MIRTAZAPINE PRODUCT
[5]
[Anonymous], J NEUROLOGICAL SCI, DOI 10.1016/j.jns.2013.07.955
[6]
[Anonymous], WELLB 40 BUPR HYDR E
[7]
[Anonymous], EFF XR CAPS VENL HYD
[8]
[Anonymous], MAUDE ADV EV REP NEU
[9]
[Anonymous], CEL CIT HYDR PROD MO
[10]
[Anonymous], CYMB DUL PROD MON